Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Clinicopathologic and molecular summary information for <i>BRAF</i>-mutant patients in the combined cohort, stratified by functional classes 1, 2, and 3. The presence of concomitant pathogenic mutations in <i>KRAS</i>, <i>NRAS</i>, or <i>NF1</i> is shown for each class. In addition to the data in the table, a single instance of co-occurring class 2 and 3 <i>BRAF</i> mutations was found. Unclassified mutations are assumed to be passenger changes for the purpose of our analysis. WT <i>BRAF</i> colorectal cancers within the combined cohort are included for reference. Percentages shown in parentheses reflect the proportion of total samples with available data for a given variable.</p>

Original publication

DOI

10.1158/1541-7786.28703696

Type

Publication Date

01/04/2025